Immunomic Therapeutics Licenses Investigational Canine Dermatitis Therapy to ZENOAQ

ROCKVILLE, Md.–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;#allergieslt;/agt;–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based
biotechnology company, announced today that the company has granted
Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd,
Koriyama, Japan) an exclusive license to develop and commercialize its
investigational DNA vaccine, ITI-002, for canine atopic dermatitis and
other companion animal allergies. The therapy was developed using ITI’s
proprietary UNITE™ (UNiversal Intracellular Targeted Expression)
platform, which harnesses the natural biochemistry of humans and other
mammals to develop vaccines that trigger broad immune responses.

“Our UNITE platform continues to generate sophisticated investigational
DNA and RNA vaccines for indications in both humans and animals,” said
Dr. William Hearl, CEO of Immunomic Therapeutics. “Investigating the
application of our technology to this significant health problem for
dogs has been an important part of our allergy research and development
program for the last few years. We are very pleased to have such a
strong animal health partner in ZENOAQ to continue the development
process and strive to bring this product to market. We are confident
with their extensive experience in the animal health market and believe
that they will be able to commercialize this potentially high-value
treatment for dog allergy worldwide.”

Atopic dermatitis is a chronic inflammatory skin condition that affects
an estimated 10-15 percent of dogs1. The disease is caused by
an allergic reaction to common environmental substances, such as grass,
dust mites, and mold. ITI’s experimental vaccine is designed to build
tolerance to a number of these allergens through the delivery of key
nucleotide sequences (for example, those encoding for dust mites).

“Canine atopic dermatitis is a life-long condition that negatively
impacts both the animal and its owner,” said ZENOAQ President Toshikazu
Fukui. “Immunomic’s immunotherapy platform combines many technological
and scientific advances, producing vaccines that could really usher in a
new era of treatment, targeting the root cause of the inflammation.”

As part of the agreement, ZENOAQ will also receive exclusive rights to
option other UNITE-based therapies and indications within animal health,
including oncology.


ITI’s investigational UNITE platform, or UNiversal Intracellular
Targeted Expression, is thought to work by encoding the Lysosomal
Associated Membrane Protein, an endogenous protein in humans. In this
way, ITI’s vaccines (DNA or RNA) have the potential to utilize the
body’s natural biochemistry to develop a broad immune response including
antibody production, cytokine release and critical immunological memory.
This approach could put UNITE technology at the crossroads of
immunotherapies in a number of illnesses, including cancer, allergy and
infectious diseases. UNITE is currently being employed in Phase II
clinical trials as a cancer immunotherapy. ITI is also collaborating
with academic centers and biotechnology companies to study the use of
UNITE in cancer types of high mortality, including cases where there are
limited treatment options like glioblastoma and acute myeloid leukemia.
ITI believes that these early clinical studies may provide a proof of
concept for UNITE therapy in cancer, and if successful, set the stage
for future studies, including combinations in these tumor types and
others. Preclinical data is currently being developed to explore whether
LAMP nucleic acid constructs may amplify and activate the immune
response in highly immunogenic tumor types and be used to create immune
responses to tumor types that otherwise do not provoke an immune
response and be used to create immune responses to tumor types that
otherwise do not provoke an immune response.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage
biotechnology company pioneering the study of the LAMP-based nucleic
acid immunotherapy platforms. These investigational technologies have
the potential to alter how we use immunotherapy for cancer, allergies
and animal health. ITI has entered into a significant licensing
agreement with Astellas Pharma Inc. to explore the use of LAMP-Vax, the
precursor to UNITE, an immunotherapy platform, for use in the prevention
and treatment of allergic diseases. For information about ITI and UNITE
technology, visit

About Zenoaq (

Established in 1946, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd.) is a
leading animal health company in Japan. With a workforce of nearly 700
employees and the generation of about ¥32.7 billion in sales
(approximately US$297.3 million) in the 2016 fiscal year, ZENOAQ has a
solid business model focused on R&D, manufacturing and importation of
animal health products, contributing to a broad product portfolio for
production and companion animals. In addition, ZENOAQ, headquartered in
Fukushima, has the widest distribution network for veterinary products
in Japan, supported by a strong direct sales force. In June 2014, ZENOAQ
launched Allermmune HDM, a first-of-its-kind desensitization therapy for
house dust mite-induced canine atopic dermatitis, reflecting the
company’s increased focus on an innovative pipeline for the companion
animal market. ZENOAQ’s partners include Boehringer Ingelheim Animal
Health, CEVA SA, Vetoquinol, Mars, Intervet, DSM Nutrition as well as
IDEXX Laboratories.

1 Hillier A, Griffin CE. The ACVD task force on canine atopic
dermatitis (I): incidence and prevalence. Vet Immunol
Immunopathology. 2001;81(3–4):147–151. doi:


Immunomic Therapeutics, Inc.
Amy Conrad
Juniper Point

Akemi Sakai
ZENOAQ Tokyo Branch Office
3 5282-2485

error: Content is protected !!